+91 789 2456 581 | info@nckpharma.com
Category

New Drug Approval

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused...
Read More
1 2 3 12

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.